Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
European Association of Urology Congress 2024
AACR Annual Meeting 2024
2024 Miami Breast Cancer Conference
2024 Society of Surgical Oncology Annual Meeting
2024 EBCC
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Conquer Cancer Foundation
November 10, 2018
Advertisement
Advertisement
Advertisement
Apr
16
Today In Oncology
Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer
ALK-Positive NSCLC Adjuvant Alectinib vs Platinum-Based Chemotherapy
Cabozantinib in Advanced Adrenocortical Carcinoma
Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk
View More
Advertisement
